However, the combination of IHCH9033 and quizartinib significantly reduced cell viability (Fig. 4h) and exhibited increased levels of γH2AX and caspase-3 cleavage (Fig. 4i), indicating enhanced DNA damage and cell apoptosis in primary FLT3-ITD AML samples compared with either treatment alone. This evidence concerns the gene CASP3 and acute myeloid leukemia.